Please login to the form below

Not currently logged in
Email:
Password:

ArQule

This page shows the latest ArQule news and features for those working in and with pharma, biotech and healthcare.

Merck gets first approval for MET inhibitor tepotinib in Japan

Merck gets first approval for MET inhibitor tepotinib in Japan

ArQule and Kyowa Hakko abandoned their MET inhibitor tivantinib in 2017 after a string of trial failures, while GlaxoSmithKline/Exelixis’ also seem to have dropped their MET/VEGF inhibitor foretinib and

Latest news

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest appointments

  • X4 appoints John Celebi as COO X4 appoints John Celebi as COO

    Most recently, he served as chief business officer of Igenica Biotherapeutics, and has previously held senior positions at Agilent Technologies, ArQule, Biogen and Cyclis Pharmaceuticals.

  • Dr Jessie English joins Merck Dr Jessie English joins Merck

    During her two decades of work in oncology and immune-oncology research, she has also served as vice president of kinase biology at ArQule, oncology site lead for external discoveries at

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

The biggest problems facing humanity today are health-related, and the health of people, animals and our planet are inextricably linked. ...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....